HC Wainwright Estimates Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Lineage Cell Therapeutics in a research report issued on Tuesday, March 11th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.06) EPS.

Other analysts have also issued reports about the stock. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday. Maxim Group lowered their target price on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN:LCTX opened at $0.52 on Thursday. The company has a market cap of $114.66 million, a price-to-earnings ratio of -4.34 and a beta of 1.21. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61. The company’s 50-day moving average price is $0.60.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several institutional investors have recently made changes to their positions in the company. Fort Sheridan Advisors LLC boosted its position in shares of Lineage Cell Therapeutics by 71.5% during the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after acquiring an additional 23,000 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in Lineage Cell Therapeutics in the fourth quarter valued at approximately $29,000. HighTower Advisors LLC boosted its holdings in shares of Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after acquiring an additional 19,100 shares during the period. SG Americas Securities LLC boosted its stake in shares of Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after buying an additional 18,053 shares during the period. Finally, Two Sigma Advisers LP increased its position in Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock valued at $44,000 after acquiring an additional 65,864 shares during the period. 62.47% of the stock is owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.